Delivery Order SPE2DB22D1103-SPE2DB25FH3K9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,567.58 to AmerisourceBergen Drug Corp for the supply of Posaconazole DR 100 mg tablets (60-count). This competitive award, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, utilizes firm fixed pricing and carries no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order valued at $7,911.53 to AmerisourceBergen Drug Corp for the supply of Posaconazole DR 100 mg tablets (60-count units) on July 25, 2025, with completion targeted for July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $2,055.80 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Posaconazole 300 mg/16.7 ml vials. The contract, with an ultimate completion date of July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.999 billion through December 2026. This award carries no set-aside...
- The Defense Logistics Agency awarded a $9,298.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Posaconazole DR 100 mg tablets in unit-dose packaging of 20s. This contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, was competitively awarded with no set-aside designation and is scheduled for completion by September 10, 2025. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Posaconazole 200 mg/5 mL suspension (105 mL) valued at $9,864.11 on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a single pharmaceutical delivery under the DLA's medical supply...
- This federal contract award, valued at $1,254.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 60 tablets of POSACONAZOLE DR 100 MG, a prescription medication, with a performance period extending until April 29, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Posaconazole delayed-release 100 mg tablets. The contract, valued at $1,106.69, has a period of performance through July 26, 2024. The contract is a firm fixed-price delivery order and was not set aside for any specific business category. AmerisourceBergen, through its Corporate Office division, has been awarded numerous federal contracts...
- This federal contract award is for the delivery of Posaconazole delayed-release 100 mg tablets, in quantities of 60, to the Defense Logistics Agency (DLA) Troop Support Medical division. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, which has a for-profit business structure. The contract is a firm fixed price delivery order with a potential value of $1,651.08. The award does not utilize any set-aside...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,469.43, is for the supply of POSACONAZOLE DR 100 MG TABLET 60S, a medication used for the treatment of certain fungal infections. The contract is a firm fixed-price delivery order with a final completion date of July 5, 2024. The contract does not have a set-aside designation, indicating it...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order valued at $19,423.07 to Amerisourcebergen Drug Corporation for 4562164267 Posaconazole 100 mg tablets, 60 count per bottle. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is short, spanning just one day from September 13 to September 14, 2023. No major subcontractors or set aside designations were indicated. This delivery...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH3K9Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for 60 tablets of Posaconazole 100 mg, an antifungal medication commonly used in military and federal healthcare settings. The contract, valued at $1,046.68 with a firm fixed price structure, was awarded on September 26, 2025, and carries an ultimate completion date of September 29, 2025. The award represents a non-competitive, non-set-aside delivery order, and performance will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a prime vendor for the DLA's Medical Supply Chain, AmerisourceBergen Drug Corp leverages this comprehensive contract vehicle to supply pharmaceutical products and medical supplies in support of military healthcare programs globally. The company's role as a critical pharmaceutical distributor for federal medical procurement demonstrates its established capability to meet Defense Department medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 9/26/25 |